Amir discusses challenges encountered during the administration process, offering valuable perspectives on the practical considerations and complexities in delivering these innovative therapies.
Daratumumab Plus KRd May Be a New SOC Option in NDMM
Daratumumab plus KRd improved MRD-negativity and PFS vs KRd alone in patients with newly diagnosed multiple myeloma.
Mitigating AEs and Protecting QOL Following Talquetamab in Multiple Myeloma
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
Daratumumab Combo Improves Outcomes in Transplant-Ineligible NDMM Subgroups
Subgroup data from the CEPHEUS trial reinforce daratumumab plus bortezomib, lenalidomide, and dexamethasone as a standard of care in this population.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Belantamab Mafodotin Combo Elicits PFS in R/R Multiple Myeloma
PFS was improved with belantamab mafodotin triplet for patients with relapsed/refractory multiple myeloma with high-risk cytogenetics.
Talquetamab Elicits Durable Responses, Survival in R/R Multiple Myeloma
The safety profile of talquetamab continued to show a lower high-grade infection risk relative to other approved anti-BCMA bispecific antibodies.